natgillin/translations-raw huggingface dataset:
In patients between 3 months and 1 year (n=2), AUC was 5,914 ng·h/mL (CV: 85%) and in patients between 1 and 2 years (n=7), AUC was 3,507 ng·h/mL (CV: 70%).
U bolesnika starosti između 3 mjeseca i 1 godine (n = 2) AUCτ je bila 5914 ng•h/mL (CV: 85%) i u bolesnika starosti između 1 i 2 godine (n = 7), AUCτ je bila 3507 ng•h/mL (CV: 70%).
In patients between 3 months and 2 years, the daily exposure was 7,879 ng·h/mL; AUC was 3,939 ng·h/mL (CV: 72%).
U bolesnika starosti između 3 mjeseca i 2 godine dnevna izloženost bila je 7879 ng•h/mL; AUCτ je bila 3939 ng•h/mL (CV: 72%).
In patients co-infected with HCV/HIV, limited efficacy and safety data (N = 25) are available in subjects with CD4 counts less than 200 cells/µl.
Među bolesnicima istodobno zaraženima HCV-om i HIV-om malo je podataka o djelotvornosti i sigurnosti (N=25) za ispitanike s brojem CD4 stanica manjim od 200 stanica/μl.
In patients co-infected with hepatitis B or C virus receiving rilpivirine, the incidence of hepatic enzyme elevation was higher than in patients receiving rilpivirine who were not co-infected.
U bolesnika istovremeno zaraženih virusom hepatitisa B ili C koji primaju rilpivirin, incidencija povišenja jetrenih enzima bila je veća nego u bolesnika koji su primali rilpivirin i nisu bili istovremeno zaraženi tim virusima.
In patients concomitantly treated with carbamazepine and eslicarbazepine acetate in placebo- controlled studies, the following adverse reactions were observed: diplopia (11.4% of subjects with concomitant carbamazepine, 2.4% of subjects without concomitant carbamazepine), abnormal coordination (6.7% with concomitant carbamazepine, 2.7% without concomitant carbamazepine), and dizziness (30.0% with concomitant carbamazepine, 11.5% without concomitant carbamazepine), see section 4.5.
U bolesnika istodobno liječenih karbamazepinom i eslikarbazepinacetatom u placebm o-kontroliranim studijama primijećene su sljedeće nuspojave: diplopija (11,4% ispitanika koji su istodobno primali karbamazepin, 2,4% ispitanika koji nisu istodobno primali karbamazepin), poremećaj koordinacije (6,7% s istodobnom primjenom karbamazepina, 2,7% bez istodobne primjene karbamazepina), i omaglica (30,0% s istodobnom primjenom karbamazepina, 11,5% bez istodobne primjene karbamazepina), vidjeti dio 4.5.
In patients concomitantly treated with carbamazepine and eslicarbazepine acetate in placebo- controlled studies, the following adverse reactions were observed: diplopia (11.4% of subjects with concomitant carbamazepine, 2.4% of subjects without concomitant carbamazepine), abnormal coordination (6.7% with concomitant carbamazepine, 2.7% without concomitant carbamazepine), and dizziness (30.0% with concomitant carbamazepine, 11.5% without concomitant carbamazepine), see section 4.5.
U bolesnika istodobno liječenih karbamazepinom i eslikarbazepinacetatom u placebom -kontroliranim studijama primijećene su sljedeće nuspojave: diplopija (11,4% ispitanika koji su istodobno primali karbamazepin, 2,4% ispitanika koji nisu istodobno primali karbamazepin), poremećaj koordinacije (6,7% s istodobnom primjenom karbamazepina, 2,7% bez istodobne primjene karbamazepina), i omaglica (30,0% s istodobnom primjenom karbamazepina, 11,5% bez istodobne primjene karbamazepina), vidjeti dio 4.5.
In patients concomitantly treated with carbamazepine and eslicarbazepine acetate in placebo- controlled studies, the following adverse reactions were observed: diplopia (11.4% of subjects with concomitant carbamazepine, 2.4% of subjects without concomitant carbamazepine), abnormal coordination (6.7% with concomitant carbamazepine, 2.7% without concomitant carbamazepine), and dizziness (30.0% with concomitant carbamazepine, 11.5% without concomitant carbamazepine), see section 4.5.
U bolesnika istodobno liječenih karbamazepinom i eslikarbazepinacetatom u placebom kontroliranim studijama primijećene su sljedeće nuspojave: diplopija (11,4% ispitanika koji su istodobno primali karbamazepin, 2,4% ispitanika koji nisu istodobno primali karbamazepin), poremećaj koordinacije (6,7% s istodobnom primjenom karbamazepina, 2,7% bez istodobne primjene karbamazepina), i omaglica (30,0% s istodobnom primjenom karbamazepina, 11,5% bez istodobne primjene karbamazepina), vidjeti dio 4.5.
In patients defined as INCAT non-responders, muscle strength improved by 5.5 points (95% confidence interval [0.6, 10.2]) as compared to INCAT responders (7.4 points (95% confidence interval [4.0, 11.7])
U bolesnika koji su definirani kao oni koji prema ljestvici INCAT ne reagiraju na liječenje, snaga mišića poboljšala se za 5,5 bodova (interval pouzdanosti 95% [0,6; 10,2] u usporedbi s INCAT bolesnicima koji su odgovorili na liječenje (7,4 bodova (95% interval pouzdanosti [4,0; 11,7])
In patients developing PRES, Bortezomib Hospira should be discontinued.
U bolesnika u kojih se razvije PRES, mora se prekinuti primjena Bortezomiba Hospira.
In patients developing PRES, VELCADE should be discontinued.
U bolesnika u kojih se razvije PRES, mora se prekinuti primjena VELCADEa.
In patients developing sudden lack of efficacy, defined by a decrease in haemoglobin (1-2 g/dl per month) with increased need for transfusions, a reticulocyte count should be obtained and typical causes of non-response (e.g. iron, folate, or Vitamin B12-deficiency, aluminium intoxication, infection or inflammation, blood loss, and haemolysis) should be investigated.
Kod bolesnika kod kojih se pojavi iznenadan izostanak djelotvornosti definiran smanjenjem hemoglobina (1-2 g/dl mjesečno) s povećanom potrebom transfuzije, potrebno je odrediti broj retikulocita i ispitati tipični uzrok neodgovaranja na terapiju (npr. nedostatak željeza, folata ili vitamina B12, trovanje aluminijem, infekcija ili upala, gubitak krvi i hemoliza).
In patients either ‘ALK-positive’ or ‘ROS1-positive’, the ALK or ROS1 protein is abnormally active and can promote the growth of cancer cells and the development of new blood vessels that supply them.
U bolesnika koji su bilo „ALK pozitivni” ili „ROS1-pozitivni”, protein ALK ili ROS1 abnormalno je aktivan te može pospješiti rast stanica raka i razvoj novih žila koje ih opskrbljuju krvlju.
In patients experiencing early diarrhea, therapeutic and prophylactic atropine should be considered unless contraindicated.
U bolesnika koji su imali rani proljev, potrebno je uzeti u obzir terapijsko ili profilaktičko liječenje atropinom, osim u slučaju kad je kontraindicirano.
In patients followed from month 24 onwards and treated with uncontrolled, open-label Visudyne treatment as needed, long-term extension data suggest that month-24 vision outcomes may be sustained for up to 60 months.
Podaci o dugoročnom praćenju bolesnika od 24 mjeseca nadalje, koji su primali Visudyne prema potrebi, na nekontrolirani način i znajući što primaju, upućuju na zaključak da se klinička korist postignuta do 24 mjeseca može održati do 60 mjeseci.
In patients for whom ciclosporin withdrawal is either unsuccessful or cannot be attempted, the combination of ciclosporin and Rapamune should not be maintained for more than months post-transplantation.
U bolesnika u kojih ukidanje ciklosporina nije bilo uspješno ili izvedivo, kombinaciju ciklosporina i Rapamunea ne smije se nastaviti duže od 3 mjeseca nakon transplantacije.
In patients for whom monotherapy is inadequate, Ferriprox may be used with deferoxamine at the standard dose (75 mg/kg/day) but should not exceed 100 mg/kg/day.
Kod bolesnika kod kojih je monoterapija neodgovarajuća, Ferriprox se može koristiti s deferoksaminom u standardnoj dozi (75 mg/kg/dan) ali doza ne bi smjela prijeći 100 mg/kg/dan.
In patients given a thrombolytic, severe haemorrhage occurred in 1.3% of the fondaparinux patients and in 2.0% of controls.
Od bolesnika koji su primali trombolitik, veliko krvarenje je nastupilo u 1,3% bolesnika u skupini liječenoj fondaparinuksom i u 2,0% bolesnika u kontrolnoj skupini.
In patients given intravenous infusions of 250 mg/m2 rituximab followed by intravenous injections of 15 MBq/kg of [90Y]-radiolabelled Zevalin, the median serum effective half-life of ibritumomab tiuxetan [90Y] was 28 h.
U bolesnika kojima se davala intravenska infuzija rituksimaba u dozi od 250 mg/m2 praćena intravenskim injekcijama od 15 MBq/kg Zevalina radioaktivno označenog izotopom [90Y] medijan efektivnog poluvijeka ibritumomab tiuksetana [90Y] u serumu iznosio je 28 sati.
in patients in the perioperative liver transplantation period and in neonates up to 4 weeks of age (see section 4.4).
kod bolesnika koji će biti podvrgnuti transplantaciji jetre i kod novorođenčadi do 4 tjedna starosti (vidjeti dio 4.4).
In patients in whom rifampicin or other CYP3A4 inducers are indicated, alternative medicinal products with less enzyme induction potential should be used.
U bolesnika u kojih je indicirana primjena rifampicina ili drugih induktora CYP3A4 moraju se koristiti alternativni lijekovi koji slabije induciraju taj enzim.
in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance
u bolesnika u kojih glikemija nije dovoljno dobro regulirana samo dijetom i tjelovježbom i u kojih primjena metformina nije primjerena zbog kontraindikacija ili nepodnošenja.
in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance.
u bolesnika neodgovarajuće kontroliranih samo dijetom i tjelovježbom i u kojih metformin nije prikladan za liječenje zbog kontraindikacija ili nepodnošljivosti.
in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance.
u bolesnika u kojih glikemija nije dovoljno dobro regulirana samo dijetom i tjelovježbom i u kojih primjena metformina nije primjerena zbog kontraindikacija ili nepodnošenja.
in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance.
u bolesnika čija se bolest ne može kontrolirati samo dijetom i tjelovježbom i za koje je metformin neprikladan zbog kontraindikacija ili nepodnošenja.
in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to intolerance, or contraindicated due to renal impairment.
za bolesnike kod kojih se samom prehranom i fizičkom aktivnošću ne postiže odgovarajuća kontrola glikemije, a kod kojih je metformin neodgovarajuća terapija zbog nepodnošljivosti ili je kontraindiciran zbog oštećenja bubrega.
In patients inadequately controlled on sulphonylurea alone or in combination with metformin, the reduction was 3.5 mmHg with Xultophy and 3.2 mmHg with placebo.
U bolesnika nedovoljno reguliranih sulfonilurejom samom ili u kombinaciji s metforminom smanjenje je iznosilo 3,5 mmHg uz Xultophy te 3,2 mmHg uz placebo.
in patients inadequately controlled on their maximally tolerated dose of metformin alone
u bolesnika u kojih glikemija nije dovoljno dobro regulirana najvećom podnošljivom dozom samog metformina
in patients inadequately controlled on their maximally tolerated dose of metformin alone
u bolesnika u kojih nije postignuta zadovoljavajuća regulacija uz njihovu maksimalnu podnošljivu dozu metformina kao monoterapije
in patients inadequately controlled with metformin in combination with other glucose-lowering medicinal products, including insulin (see sections 4.5 and 5.1 for available data on different combinations) in patients already being treated with the combination of empagliflozin and metformin as separate tablets.
u bolesnika u kojih nije postignuta zadovoljavajuća regulacija metforminom u kombinaciji s drugim lijekovima za snižavanje glukoze u krvi, uključujući inzulin (vidjeti dijelove 4.5 i 5.1. za dostupne podatke o različitim kombinacijama) u bolesnika koji se već liječe kombinacijom empagliflozina i metformina kao odvojenim tabletama.
In patients included in the clinical trial, 40%- 50% of patients had platelet counts below the lower limit of normal at baseline.
Kod bolesnika uključenih u kliničko ispitivanje, 40%-50% bolesnika broj trombocita na početku bio je ispod donje granice normale.
In patients insufficiently controlled with 150 mg once daily, the dose of irbesartan can be increased to 300 mg, or other anti-hypertensive agents can be added (see sections 4.3, 4.4, 4.5 and 5.1).
U bolesnika u kojih se bolest ne može dostatno kontrolirati dozom od 150 mg jedanput na dan, doza irbesartana može se povećati na 300 mg ili se mogu dodati drugi antihipertenzivi (vidjeti dijelove 4.3, 4.4, 4.5 i 5.1).
In patients insufficiently controlled with 150 mg once daily, the dose of Irbesartan Zentiva can be increased to 300 mg, or other antihypertensive agents can be added (see sections 4.3, 4.4, 4.5 and 5.1).
U bolesnika u kojih se bolest ne može dostatno kontrolirati dozom od 150 mg jedanput na dan, doza lijeka Irbesartan Zentiva može se povećati na 300 mg ili se mogu dodati drugi antihipertenzivi (vidjeti dijelove 4.3, 4.4, 4.5 i 5.1) .
In patients insufficiently controlled with 150 mg once daily, the dose of Irbesartan Zentiva can be increased to 300 mg, or other antihypertensive agents can be added (see sections 4.3, 4.4, 4.5 and 5.1)..
U bolesnika u kojih se bolest ne može dostatno kontrolirati dozom od 150 mg jedanput na dan, doza lijeka Irbesartan Zentiva može se povećati na 300 mg ili se mogu dodati drugi antihipertenzivi (vidjeti dijelove 4.3, 4.4, 4.5 i 5.1).
In patients insufficiently controlled with 150 mg once daily, the dose of Karvea can be increased to 300 mg, or other antihypertensive agents can be added (see sections 4.3, 4.4, 4.5 and 5.1).
U bolesnika u kojih se bolest ne može dostatno kontrolirati dozom od 150 mg jedanput na dan, doza lijeka Karvea može se povećati na 300 mg ili se mogu dodati drugi antihipertenzivi (vidjeti dijelove 4.3, 4.4, 4.5 i 5.1) .
In patients not adequately controlled by irbesartan alone, the addition of a low dose of hydrochlorothiazide (12.5 mg) to irbesartan once daily results in a further placebo-adjusted blood pressure reduction at trough of 7-10/3-6 mm Hg (systolic/diastolic).
U bolesnika koji nisu prikladno kontrolirani samo s ibesartanom, dodatak niske doze hidroklorotiazida (12,5 mg) irbesartanu jedanput na dan rezultira dodatnim placebo prilagodenim sniženjem krvnog tlaka za 7-10/3-6 mm Hg (sistolički/dijastolički).
In patients not adequately controlled by irbesartan alone, the addition of a low dose of hydrochlorothiazide (12.5 mg) to irbesartan once daily results in a further placebo-adjusted blood pressure reduction at trough of 7-10/3-6 mm Hg (systolic/diastolic).
U bolesnika koji nisu prikladno kontrolirani samo s ibesartanom, dodatak niske doze hidroklorotiazida (12,5 mg) irbesartanu jedanput na dan rezultira dodatnim placebo prilagođenim sniženjem krvnog tlaka za 7-10/3-6 mm Hg (sistolički/dijastolički).
In patients not adequately controlled on 25 mg hydrochlorothiazide alone, the addition of irbesartan gave an added placebo-subtracted systolic/diastolic mean reduction of 11.1/7.2 mm Hg.
Bolesnicima čiji se tlak ne može učinkovito kontrolirati samo sa 25 mg hidroklorotiazida, dodatak irbesartana omogućuje dodatno smanjenje sistoličkog/dijastoličkog tlaka korigirano za placebo za prosječno 11,1/7,2 mmHg.
In patients not adequately controlled on metformin alone or in combination with other glucose-lowering medicinal products, including insulin, the recommended starting dose of Synjardy should provide empagliflozin 5 mg twice daily (10 mg daily dose) and the dose of metformin similar to the dose already being taken.
U bolesnika u kojih nije postignuta zadovoljavajuća regulacija uz metformin kao monoterapiju ili u kombinaciji s drugim lijekovima za snižavanje glukoze u krvi, uključujući inzulin, preporučena početna doza lijeka Synjardy mora osigurati 5 mg empagliflozina dvaput dnevno (dnevna doza 10 mg) i dozu metformina sličnu dozi koja se već uzima.
in patients not adequately controlled on their maximally tolerated doses of metformin alone
u bolesnika koji uz maksimalno podnošljive doze metformina u monoterapiji nemaju adekvatnu regulaciju
In patients not also taking ciclosporin, concomitant administration of CellCept and rifampicin resulted in a decrease in MPA exposure (AUC0-12h) of 18% to 70%.
Kod bolesnika koji ne uzimaju i ciklosporin, istodobna primjena lijeka CellCept i rifampicina rezultirala je smanjenjem izloženosti MPA-u (AUC0–12 h) od 18% do 70%.
In patients not also taking ciclosporin, concomitant administration of mycophenolate mofetil and rifampicin resulted in a decrease in MPA exposure (AUC0-12 h) of 18 % to 70 %.
Kod bolesnika koji ne uzimaju i ciklosporin, istodobna primjena mofetilmikofenolata i rifampicina rezultirala je smanjenjem izloženosti MPA-u (AUC0–12 h) od 18 % do 70 %.
In patients not also taking ciclosporin, concomitant administration of mycophenolate mofetil and rifampicin resulted in a decrease in MPA exposure (AUC0-12h) of 18% to 70%.
Kod bolesnika koji ne uzimaju i ciklosporin, istodobna primjena mofetilmikofenolata i rifampicina rezultirala je smanjenjem izloženosti MPA-u (AUC0–12 h) od 18% do 70%.
In patients not also taking ciclosporin, concomitant administration of mycophenolate mofetil and rifampicin resulted in a decrease in MPA exposure (AUC0-12h) of 18% to 70%.
Kod bolesnika koji ne uzimaju i ciklosporin, istodobna primjena mofetilmikofenolata i rifampicina rezultirala je smanjenjem izloženosti MPA-u (AUC0–12 sati) od 18% do 70%.
In patients not given concomitant methotrexate, the incidence was 12.4%, compared to 0.6% when adalimumab was used as add-on to methotrexate.
U bolesnika koji istodobno nisu primali metotreksat incidencija je bila 12,4% u odnosu na 0,6% u skupini bolesnika kojima je dodan adalimumab uz metotreksat.
In patients not given concomitant methotrexate, the incidence was 13.6% (3/22), compared to 8.3% (2/24) when adalimumab was used as add-on to methotrexate.
U bolesnika koji nisu istodobno primili metotreksat incidencija je bila 13,6% (3/22), u usporedbi s 8,3% (2/24) u bolesnika kojima je dodan adalimumab uz metotreksat.
In patients not given concomitant methotrexate, the incidence was 16/185 (8.6%), compared to 1/19 (5.3%) when adalimumab was used as add-on to methotrexate.
U bolesnika koji nisu istodobno primali metotreksat pojavnost protutijela na adalimumab protutijela bila je 16/185 (8,6%) u usporedbi s 1/19 (5,3%) bolesnika koji su primali adalimumab uz metotreksat.
In patients not given concomitant methotrexate, the incidence was 25.6% (22/86) compared to 5.9% (5/85) when adalimumab was used as add-on to methotrexate.
U bolesnika koji nisu istodobno primili metotreksat incidencija je bila 25,6% (22/86), u usporedbi s 5,9% (5/85) u bolesnika kojima je dodan adalimumab uz metotreksat.
In patients not given concomitant methotrexate, the incidence was 25.6% (22/86), compared to 5.9% (5/85) when adalimumab was used as add-on to methotrexate.
U bolesnika koji nisu istodobno primili metotreksat incidencija je bila 25,6% (22/86), u usporedbi s 5,9% (5/85) u bolesnika kojima je dodan adalimumab uz metotreksat.
In patients not on dialysis, Aranesp may continue to be administered as a single injection once weekly or once every two weeks or once monthly.
Kod bolesnika koji nisu na dijalizi, može se nastaviti s primjenom Aranespa kao pojedinačne injekcije jednom tjedno ili jednom svaka dva tjedna ili jednom mjesečno.
In patients not on palliative care, Relistor is given as an injection under the skin at a dose of 12 mg once a day, for 4 to 7 days per week; treatment with usual laxatives should be stopped when starting Relistor.
U bolesnika koji ne primaju palijativnu skrb, Relistor se primjenjuje kao potkožna injekcija u dozi od 12 mg jednom na dan tijekom 4 do 7 dana tjedno; ukoliko se započinje terapija lijekom Relistor, liječenje uobičajenim laksativima treba prekinuti.
In patients not previously treated with RoActemra, initiation is not recommended in patients with an absolute neutrophil count (ANC) below 2 x 109/l.
Kod bolesnika koji prije nisu bili liječeni lijekom RoActemra, uvođenje lijeka RoActemra se ne preporučuje ako je apsolutni broj neutrofila (ABN) manji od 2 x 109/l.
In patients of 18 years and older, according to the indication, the treatment regimen will be:
U bolesnika u dobi od 18 ili više godina režim liječenja će, sukladno indikaciji, biti:
In patients of 18 years and older:
U bolesnika u dobi od 18 ili više godina:
in patients of at least 75 years old but less than 80 years, the dose of vinflunine to be given is 280 mg/m² every 3 weeks. in patients 80 years old and above, the dose of vinflunine to be given is 250 mg/m² every 3 weeks.
u bolesnika koji imaju najmanje 75 godina, ali manje od 80 godina, doza vinflunina koja se primjenjuje je 280 mg/m² svaka 3 tjedna. u bolesnika koji imaju 80 ili više godina doza vinflunina koja se primjenjuje je 250 mg/m² svaka 3 tjedna.
In patients on chronic warfarin therapy, the International Normalised Ratio (INR) should be monitored closely for 14 days following the use of fosaprepitant (see section 4.5).
U bolesnika na kroničnom liječenju varfarinom treba strogo nadzirati međunarodni normalizirani omjer (INR) tijekom 14 dana nakon primjene fosaprepitanta (vidjeti dio 4.5).
In patients on insulin with no pioglitazone the incidence of heart failure was 8.2% in those ≥ 65 years compared to 4.0% in patients less than 65 years.
U bolesnika na inzulinu bez pioglitazona, incidencija srčanog zatajenja bila je 8,2% kod osoba u dobi ≥65 godina, u odnosu na 4,0% u bolesnika mlađih od 65 godina.
In patients on insulin with no pioglitazone the incidence of heart failure was 8.2% in those ≥65 years compared to 4.0% in patients less than 65 years.
U bolesnika na inzulinu bez pioglitazona, incidencija srčanog zatajenja bila je 8,2% u osoba u dobi≥65 godina, u odnosu na 4,0% u bolesnika mlađih od 65 godina.
In patients on leflunomide treatment presenting unexplained chronic diarrhoea appropriate diagnostic procedures should be performed.
U bolesnika koji primaju terapiju leflunomidom, a u kojih je prisutan neobjašnjiv kronični proljev potrebnoje provesti odgovarajuće dijagnostičke postupke.
in patients on their maximally tolerated doses of metformin along with other glucose-lowering medicinal products including insulin, when these do not provide adequate glycaemic control (see sections 4.4, 4.5, and 5.1 for available data on different add-on therapies) in patients already being treated with the combination of canagliflozin and metformin as separate tablets.
u bolesnika kod kojih maksimalne podnošljive doze metformina, zajedno s drugim lijekovima koji snižavaju glukozu uključujući inzulin, ne omogućavaju adekvatnu regulaciju glikemije (za dostupne podatke o različitim vrstama dodatnih terapija vidjeti dijelove 4.4, 4.5 i 5.1) u bolesnika koji se već liječe kombinacijom kanagliflozina i metformina u pojedinačnim tabletama.
In patients over 75 years of age a starting dose of 100 mg (2 capsules) a day is recommended.
Za bolesnike starije od 75 godina preporuča se početna doza od 100 mg (2 kapsule) dnevno.
In patients pramipexole alleviates signs and symptoms of idiopathic Parkinson’s disease.
U bolesnika pramipeksol otklanja znakove i simptome idiopatske Parkinsonove bolesti.
In patients pramipexole alleviates signs and symptoms of idiopathic Parkinson’s disease.
U bolesnika, pramipeksol otklanja znakove i simptome idiopatske Parkinsonove bolesti.
In patients presenting with fever, neutropenia, and a compatible pattern of abdominal pain, the possibility of neutropenic colitis should be considered.
U bolesnika s vrućicom, neutropenijom i bolovima u trbuhu koji upućuju na tu bolest, potrebno je posumnjati na neutropenični kolitis.
In patients presenting with fever, neutropenia, and a compatible pattern of abdominal pain, the possibility of neutropenic colitis should be considered.
U bolesnika s vrućicom, neutropenijom i odgovarajućim oblikom boli u abdomenu, potrebno je posumnjati na neutropenični kolitis.